...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Acta Interna: The Journal of Internal Medicine >Impressive Result of Gemcitabine and Cisplatin Combination Therapy in Post-Operative Residual Cholangiocarcinoma Patient Presenting with Hyperbilirubinemia, an Experience in Indonesian Tertiary Hospital
【24h】

Impressive Result of Gemcitabine and Cisplatin Combination Therapy in Post-Operative Residual Cholangiocarcinoma Patient Presenting with Hyperbilirubinemia, an Experience in Indonesian Tertiary Hospital

机译：吉西他滨和顺铂联合治疗在术后残留胆管癌患者患有高胆管素血症的令人印象深刻的结果，在印度尼西亚第三高级医院的经验

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Introduction: Cholangiocarcinoma (CCA) often presents at an inoperable or an advanced stage in which complete resection is not possible. In such scenario, chemotherapy often is the only option to improve patient’s survival. Severe hyperbilirubinemia, often associated with higher risk of developing chemotherapy-related adverse event, might complicates one’s decision in choosing chemotherapy regimen. Case Report: We present a case of 63-year-old post-operative CCA patient with residual mass and severe hyperbilirubinemia. The patient completed six cycles of gemcitabine (1000 mg/m~(2), day 1 and 8) and cisplatin (70 mg/m~(2), day 1) every 3 weeks with tolerable side effect. No sign of residual tumor was observed on CT-Scan performed one-month post chemotherapy. Conclusion: Combination of cisplatin and gemcitabine may offer safe treatment option for post-operative residual CCA patient presenting with hyperbilirubinemia.
机译：简介：胆管癌（CCA）通常在不可操作或高级阶段呈现出完全切除的阶段。在这种情况下，化疗通常是改善患者生存的唯一选择。严重的高胆管血症，通常与开发化疗相关的不良事件的风险较高，可能会使一个人在选择化疗方案方面的决定。案例报告：我们提出了63岁的术后CCA患者的案例，患有残留的肿块和严重的血红蛋白血症。患者在每3周内完成了六个吉西他滨（1000mg / m〜（2），第1和8天），第1天和第14天，第1天），具有可耐受的副作用。在CT扫描上没有观察到残留肿瘤的迹象表演，进行了一个月的化疗。结论：顺铂和吉西他滨的组合可为患有高胆血清血症呈现的术后残留CCA患者提供安全的治疗选择。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号